Primary Sjögren’s syndrome, blood shortages are strong predictors of poor prognosis

Results of a Spanish study showed that patients with concomitant lymphopenia , , or hypocomplementemia were more likely to development of poor results, such as lymphoma. The existence of the lung and hepatic participation has been shown that risk factors independently associated with mortality.For health care diagnosis of primary Sjogren’s syndrome , the incidence of deficiencies of the basis of the blood is the best predictor of poor prognosis patients according to results of a study presented at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. The study also showed that the involvement of the liver and lung, and non-Hodgkin’s lymphoma development were also associated with increased mortality in patients with PSS.

Two hundred and 44 patients with PSS recorded at the Vall d ‘Hebron University Hospital, Barcelona, ​​were included in this single-center study. The average age was 58 years, and clinical follow-up ranging from nine months to 20 years developed non-Hodgkin’s lymphoma, 22 patients had developed malignant tumors and 18 patients had died. Only an excess mortality lymphoproliferative malignancy was found in patients with PSS.

In particular, compared to women in the placebo group, women 60 mg of raloxifene has a statistically significant slower rate of increase of creatinine in the blood, high levels of what is the function of indicating poor kidney function. The wives of two doses of raloxifene had a statistically significant slowing in the decline in their glomerular filtration rate . GFR decreases with age. A significant decrease can be an early indicator of kidney disease that requires intervention.

Doctors are looking for drugs that slow the decline of GFR, and this study shows that raloxifene may have this effect.